Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunological Memory01:23

Immunological Memory

14.5K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
14.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.4K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
Vaccinations01:51

Vaccinations

50.5K
Overview
50.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACLY inhibition promotes tumour immunity and suppresses liver cancer.

Nature·2025
Same author

Mapping the intersection of demographics, behavior, and government response to the COVID-19 pandemic: an observational cohort study.

BMC global and public health·2025
Same author

Thermostabilization of a model viral-vectored oral thin film vaccine.

International journal of pharmaceutics·2025
Same author

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

Allergy·2023
Same author

Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management.

Research and practice in thrombosis and haemostasis·2023
Same author

Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections.

Viruses·2021

Related Experiment Video

Updated: Dec 8, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.6K

Peptide Immunotherapy; short but long lasting?

Elizabeth J Simms1, Ijlal Syed1, Christopher Rudulier1

  • 1Clinical Immunology & Allergy and Respirology Divisions, Department of Medicine and Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.

Current Treatment Options in Allergy
|September 21, 2020
PubMed
Summary

Peptide immunotherapy offers a safer alternative to traditional allergen immunotherapy (AIT) by using synthetic peptides to induce tolerance. This approach shows long-lasting efficacy and disease modification for allergic conditions with fewer adverse events.

Keywords:
Peptide immunotherapyT cell epitopeallergysynthetic peptide immunoregulatory epitope

More Related Videos

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.2K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.4K

Related Experiment Videos

Last Updated: Dec 8, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.6K
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.2K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.4K

Area of Science:

  • Immunology
  • Allergy Research
  • Therapeutic Development

Background:

  • Allergen immunotherapy (AIT) is effective but carries risks of severe allergic reactions.
  • Current AIT uses whole allergens, posing safety concerns due to IgE-mediated events.

Purpose of the Study:

  • To evaluate peptide immunotherapy as a safer and disease-modifying alternative to traditional AIT.
  • To investigate the efficacy and safety of synthetic peptide immunoregulatory epitopes (SPIRE) for allergic diseases.

Main Methods:

  • Utilized short, soluble, monomeric synthetic peptide immunoregulatory epitopes (SPIRE) derived from allergens.
  • Administered peptides via intradermal injections, focusing on T cell epitope representation.
  • Assessed clinical efficacy and adverse event profiles in early clinical trials.

Main Results:

  • Peptide immunotherapy demonstrated efficacy months to years after treatment cessation, indicating disease modification.
  • Short peptides avoided IgE-mediated adverse events, improving the safety profile compared to AIT.
  • Larger doses were administered in shorter treatment durations (e.g., four injections) with sustained efficacy.

Conclusions:

  • Peptide immunotherapy represents a promising, safer, and disease-modifying treatment for T cell-dependent allergic and autoimmune diseases.
  • The improved safety profile allows for more efficient administration and potentially greater patient compliance.
  • This approach has the potential to alter the natural history of allergic diseases.